Cogent Biosciences (COGT) Enterprise Value (2020 - 2026)

Cogent Biosciences (COGT) has reported Enterprise Value for 10 consecutive years, with -$866.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 252.67% year-over-year to -$866.4 million; the TTM figure through Mar 2026 stood at -$866.4 million (down 252.67% YoY), while the FY2025 annual figure was -$900.8 million, down 213.77% from the prior year.
• Enterprise Value improved to -$866.4 million in Q1 2026 per COGT's latest filing, from -$900.8 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$141.1 million in Q4 2022 and bottomed at -$900.8 million in Q4 2025.
• Historically, Enterprise Value has averaged -$355.7 million across 5 years, with a median of -$289.1 million in 2022.
• Annual changes were most pronounced in 2025 — Enterprise Value jumped 43.62% — and 2026, when it sank 252.67%.
• Cogent Biosciences' Enterprise Value stood at -$141.1 million in 2022, then plunged by 88.26% to -$265.7 million in 2023, then retreated by 8.04% to -$287.1 million in 2024, then plunged by 213.77% to -$900.8 million in 2025, then gained by 3.82% to -$866.4 million in 2026.
• Business Quant data shows COGT's Enterprise Value at -$866.4 million in Q1 2026, -$900.8 million in Q4 2025, and -$390.9 million in Q3 2025.